GlassScriptPhysician profile
Ruchika Bhasin
NPI 1215241740
$3,659.64
in general payments reported to CMS, 2019-2025
21 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.44 · 2020: $166 · 2021: $103 · 2022: $354 · 2023: $514 · 2024: $1,313 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $952.76 | 2020-2025 | Krystexxa, Tavneos, Epogen |
| Astrazeneca Pharmaceuticals LP | $612.01 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $424.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $305.86 | 2022-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $219.85 | 2023-2025 | |
| Lilly USA, LLC | $174.39 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $147.63 | 2024-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $97.55 | 2024-2025 | Auryxia, Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.24 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $87.89 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $86.56 | 2019-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $82.91 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $72.14 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $67.97 | 2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.46 | 2023-2024 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $48.18 | 2024 | Rayaldee |
| Horizon Therapeutics Plc | $41.20 | 2022-2023 | |
| Fresenius USA Marketing, INC. | $24.10 | 2023 | |
| Novo Nordisk INC | $22.73 | 2024 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $20.75 | 2024 | Injectafer |
| Philips North America LLC | $19.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchika Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.